Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection could smooth neck bands in phase 3 trial

NCT ID NCT07122193

Symptom relief Sponsor: Merz North America, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether NT 201 (incobotulinumtoxinA, a botulinum toxin type A injection) can safely reduce the appearance of moderate to severe neck bands (platysma prominence) compared to a placebo. About 300 adults in the US are participating in this double-blind study. The main goal is to see if the treatment improves neck band appearance by at least two grades on a five-point scale at two weeks after injection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
incobotulinumtoxinA (a botulinum toxin type A injection, also known as Xeomin)
What this could lead to
If it works, this could provide a safe and effective treatment to reduce the appearance of neck bands (platysma prominence) in adults.
What could go wrong
This is a cosmetic treatment, not a cure for any disease. Results may vary, and there are risks like allergic reactions or temporary muscle weakness. The trial is still ongoing, so final results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

300 people

The number who actually took part.

Started

Aug 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Presence of four (medial and lateral, left and right) platysmal bands assessed at screening and baseline. * A score of Grade 3 ('moderate') or Grade 4 ('severe') on the MAPS-D at maximum contraction by the investigator and participant. Exclusion Criteria: * Hypersensitivity or a history of allergic reaction to botulinum toxin of any serotype or any of their formulation ingredients. * Any medical condition that may put the participant at increased risk with exposure to botulinum toxin of any serotype, or any disorders that might interfere with neuromuscular function. * Any serious disease or disorder that could interfere with the safe completion of treatment or with study outcome assessments, or compromise participant safety. * Botulinum toxin treatment in the face (below the lower orbital rim), jawline, or neck within the last seven months. * History of lower face surgery, neck or chest surgery, and aesthetic procedures in the past 12 months, and/or orthodontic procedures in the past 6 months. * Planned surgery or aesthetic procedures to the lower face, neck, or chest during the study period. * Anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study products).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acetylcholine release inhibitors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acetylcholine release inhibitors Botulinum toxins, type A Cholinergic agents Incobotulinumtoxina Membrane transport modulators Molecular mechanisms of pharmacological action Neuromuscular agents Neurotransmitter agents Peripheral nervous system agents Physiological effects of drugs

Contacts and locations

Locations

  • Merz Investigative Site

    Scottsdale, Arizona, 85260, United States

  • Merz Investigative Site

    Encino, California, 91436, United States

  • Merz Investigative Site

    Los Angeles, California, 90069, United States

  • Merz Investigative Site

    Redondo Beach, California, 90277, United States

  • Merz Investigative Site

    Santa Monica, California, 90404, United States

  • Merz Investigative Site

    Vista, California, 92803, United States

  • Merz Investigative Site

    Greenwood Village, Colorado, 80111, United States

  • Merz Investigative Site

    Westport, Connecticut, 06880, United States

  • Merz Investigative Site

    Washington D.C., District of Columbia, 20037, United States

  • Merz Investigative Site

    Aventura, Florida, 33180, United States

  • Merz Investigative Site

    Boca Raton, Florida, 33431, United States

  • Merz Investigative Site

    Bradenton, Florida, 34209, United States

  • Merz Investigative Site

    Coral Gables, Florida, 33143, United States

  • Merz Investigative Site

    Coral Gables, Florida, 33146, United States

  • Merz Investigative Site

    West Palm Beach, Florida, 33404, United States

  • Merz Investigative Site

    Alpharetta, Georgia, 30005, United States

  • Merz Investigative Site

    Naperville, Illinois, 60563, United States

  • Merz Investigative Site

    Hunt Valley, Maryland, 21030, United States

  • Merz Investigative Site

    Mount Kisco, New York, 10549, United States

  • Merz Investigative Site

    New York, New York, 10021, United States

  • Merz Investigative Site

    New York, New York, 10028, United States

  • Merz Investigative Site

    Chapel Hill, North Carolina, 27517, United States

  • Merz Investigative Site

    Wilmington, North Carolina, 28405, United States

  • Merz Investigative Site

    Ardmore, Pennsylvania, 19003, United States

  • Merz Investigative Site

    Nashville, Tennessee, 37215, United States

  • Merz Investigative Site

    Dallas, Texas, 75225, United States

  • Merz Investigative Site

    Arlington, Virginia, 22209, United States

  • Merz Investigative Site

    San Juan, 00917, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.